Filing Flows › Comparisons › IDYA vs ZBIO
Ideaya Biosciences vs Zenas BioPharma: IDYA and ZBIO compared
Ideaya Biosciences is the larger company: $10.2M of revenue in its latest quarter (Q3 2026) against $10.0M for Zenas BioPharma (Q3 2026).
Where the money goes: IDYA and ZBIO
Ideaya Biosciences (IDYA) · Q3 2026
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
| Ideaya Biosciences (IDYA) | Zenas BioPharma (ZBIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.2M | $10.0M |
| Revenue growth, Y/Y | -95% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$126M | −$109M |
| Operating cash flow | −$93.5M | −$58.0M |
| Market value | $3.7B | — |
| Analysts’ mean target | $51.38 | — |
Questions
Which is bigger, Ideaya Biosciences or Zenas BioPharma?
Ideaya Biosciences is the larger company: $10.2M of revenue in its latest quarter (Q3 2026) against $10.0M for Zenas BioPharma (Q3 2026).
More: Ideaya Biosciences earnings · how Ideaya Biosciences makes money · Zenas BioPharma earnings · how Zenas BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.